Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 951-958

  Kressner, Ulf ^a   Lindmark, Gudrun ^a   Gerdin, Bengt ^a   Påhlman, Lars ^a   Glimelius, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal cancer; DNA ploidy; Immunohistochemistry; p53; Survival

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53; ANTIBODY; FORMALDEHYDE; PARAFFIN; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMISTRY; COLON TUMOR; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PLOIDY; PROGNOSIS; RECTUM TUMOR; SURVIVAL RATE; ANEUPLOIDY; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; FOLLOW UP; FROZEN SECTION; GENE MUTATION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029666236     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Levine AJ: The p53 tumor-suppressor gene. N Engl J Med 326: 1350-1351, 1992.
3. Chang F, Syrjanen S, Syrjänen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 4: 1009-1022, 1995.
4. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
5. Dix BR, Robbins P, Soong R, Jenner D, Hove AK, Iacopetta BJ: The common molecular genetic alteration in Dukes' B and C colorectal carcinomas are not short-term prognostic indications of survival. Int J Cancer 50: 747-751, 1994a.
6. Hamelin R, Laurent-Puig GP, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterol 106: 42-48, 1994.
7. Levine AJ, Momand J, Finlay C: The p53 tumor suppressor gene. Nature 351: 453-56, 1992.
8. Kawasaki Y, Monden T, Morimoto H, Murotani M, Miyoshi Y, Kobayashi T, Shimano T, Mori T: Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 97: 244-249, 1992.
9. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G: Increased p53 protein content of colorectal tumors correlates with poor survival. Br J Cancer 66: 758-764, 1992.
10. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P: p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63, 317-319, 1991.
11. Starzynska T, Bromley M, Ghosh A, Stern PL: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66: 558-562, 1992.
12. Goh H-S, Chan CS, Khine K, Smith DS: p53 behaviour in colorectal caner. Lancet 344: 233-234, 1994.
13. Sun XF, Carstensen JM, Stål O, Zhang, Nilsson E, Sjödahl R, Nordenskjöld B: Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virch Arch A Pathol Anat 423: 443-448, 1993.
14. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blaire GE, Taylor GR, Dixon MF, Quirke P: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterol 104: 57-64, 1994.
15. Tomoda H, Kakeji Y: Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlations and prognostic significance. J Surg Oncol 2: 125-128, 1995.
16. Hanski C, Bornhoeft G, Shimoda T, Hanski ML Lane DP, Stein H, Riecken EO: Expression of p53 protein in invasive colorectal carcinomas of different histologic types. Cancer 70: 2772-2777, 1992.
17. Yamagushi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazakii T: p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68: 399-402, 1993.
18. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M: Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70: 293-296, 1994.
19. Bosari S, Giuseppe V, Bossi P, Maggioni M, Coggi G, Murray J, Lee A. Cytoplasmatic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Canc Inst 86: 681-687, 1994.
20. Bruner JM, Connelly JH, Saya H: p53 protein immunostaining in routinely processed paraffin-embedded sections. Modern Pathol 6: 189-194, 1993.
21. Yarbro JW: Future potential of adjuvant and neoadjuvant therapy. Semin Oncol 12: 613-619, 1991.
22. Dukes CE, Bussey HJR: The spread of rectal cancer and its effects on prognosis. Br J Cancer 12: 309-320, 1958.
23. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane D, Preece PE, Andreotti PE: Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 199: 264-270, 1994.
24. Lowe SW, Ruley HE, Jacks T et al: p53-dependent apoptosis modulates the cytotoxity of anticancer agents. Cell 74: 957-967, 1993.
25. Lowe SW, Schmitt EM, Smith SW et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
26. Morson BC, Sobin LH: Histological typing of intestinal tumors. International Histological aassification of Tumors No. 15. WHO, Geneva, 1976.
27. Campani D, Cecchetti D, Bevilaqua G: Immunocytochemical p53 detection by microwave oven heating of routinely formalin-fixed paraffin sections. J Pathol 171: 151-152, 1993.
28. Lindmark G, Glimelius B, Påhlman L Enblad P: Heterogeneity in ploidy and s-phase fractions in colorectal adenocarcinomas. Int J Colored Dis 6: 115-120, 1993.
29. Lawless JF: Statistical methods and models for life-time data. Wiley, New York, 1992.
30. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al: Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Surg 35: 1-39, 1977.
31. Kressner U, Lindmark G, Gerdin B, Påhlman L, Glimelius B: Heterogeneity in proliferation markers in colorectal cancer. Anticancer Res, in press.
32. Baas IO, Mulder JWR, Offerhaus OJA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 72: 5-12, 1994.
33. Wynford-Thomas D: p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 166: 329-330, 1994.
34. Dix B, Robins P, Carello A, House A, Iacopetta B: Companson of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70: 585-90, 1994b.
35. Lane DP: p53: guardian of the genome. Nature 358: 15-16, 1992.
36. Meling GI, Lothe RA, Borresen AL: The TP53 tumor suppressor gene in colorectal carcinoma II: relation to DNA ploidy pattern and clinicopathological vanables. Br J Cancer 67: 93-98, 1993.
37. Hinds PW, Weinberg RA: Tumor suppressor genes. Curr Opin Genet Dev 4: 135-141, 1994.
38. Carder PJ, Cripps KJ, Morris R, Collins S, White S, Bird CC, Wyllie AH: Mutation of the p53 gene precedes aneuploid divergence in colorectal carcinoma. Br J Cancer 71: 215-218, 1995.
39. Rew D: Significance of aneuploidy. Br J Surg 10: 1416-1422, 1994.